Product Program year 2025 Source: CMS Open Payments

Qelbree

Drug Viloxazine Hydrochloride

NDC 17772-132-30

Open in the dashboard

General payments

$8,200,774

123,341 payments

Research payments

$0

0 payments

Through program year 2025, $8,200,774 in general payments and $0 in research payments were reported against Qelbree (Viloxazine Hydrochloride).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2025 General $3,835,805 62,201
2024 General $4,364,969 61,140

Breakdown

Who paid General payments · program years 2024–2025
  1. Supernus Pharmaceuticals, Inc. $8,147,433 122,475 payments
  2. US WorldMeds, LLC $53,341 866 payments
Top recipients General payments · program year 2025
  1. Ann Childress Child & Adolescent Psychiatry · Las Vegas, NV $88,519 2% · 83 payments
  2. Gregory Mattingley Psychiatry · Saint Charles, MO $87,294 2% · 80 payments
  3. Birgit Amann Child & Adolescent Psychiatry · Troy, MI $81,819 2% · 92 payments
  4. Richard Jackson Psychiatry · Boca Raton, FL $65,204 2% · 74 payments
  5. Michael Feld Psychiatry · Northbrook, IL $64,551 2% · 96 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Psychiatry Psychiatry & Neurology $1,350,516 36% · 1,848 practitioners
  2. Child & Adolescent Psychiatry Psychiatry & Neurology $641,974 17% · 432 practitioners
  3. Nurse Practitioner, Psychiatric/Mental Health Nurse Practitioner $476,412 13% · 4,738 practitioners
  4. Pediatrics $470,756 12% · 2,978 practitioners
  5. Physician Assistant $146,334 4% · 1,137 practitioners

The top 5 of 149 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Texas $391,175 10% · 2,111 recipients
  2. Michigan $338,085 9% · 757 recipients
  3. Florida $239,418 6% · 1,348 recipients
  4. Ohio $208,523 5% · 897 recipients
  5. Missouri $196,816 5% · 391 recipients

The top 5 of 52 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

4,091

Prescriptions dispensed, refills included

Drug cost

$2,261,603

Paid at the pharmacy, in all

Prescribers

253

With 11 or more claims of it

Medicare Part D drugs matched to Qelbree, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Qelbree Viloxazine Hcl Same name 253 4,091 $2,261,603

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Curtis Child Nurse Practitioner NV 80 $17,408 None on record
Ralph Hirschfeld Nurse Practitioner CT 61 $24,735 $1,090
Michael Miller General Surgery IN 57 $29,997 $388
Michael McIntosh Psychiatry KY 50 $40,904 $28
Paul Reardon Psychiatry & Neurology CA 45 $20,021 $29

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
123,341 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record